We are live on
!
Find out more
FCMV
Foresite Capital Management V Portfolio holdings
AUM
$271M
1-Year Est. Return
309.87%
This Fund
S&P 500
This Quarter
Est. Return
+28.78%
1 Year Est. Return
+309.87%
3 Year Est. Return
+356.88%
5 Year Est. Return
+250.56%
10 Year Est. Return
–
AUM
$135M
AUM Growth
–
Cap. Flow
+$125M
Cap. Flow
% of AUM
92.44%
Top 10 Holdings %
Top 10 Hldgs %
98.63%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$35.1M |
| 2 |
ALX Oncology
ALXO
|
+$19.2M |
| 3 |
Relay Therapeutics
RLAY
|
+$18.1M |
| 4 |
Nurix Therapeutics
NRIX
|
+$15M |
| 5 |
PHICU
Population Health Investment Co., Inc. Unit
PHICU
|
+$9.89M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $34.8M | 25.78% |
+875,001
| New | +$35.1M |
|
|
2
ALX Oncology
ALXO
$262M
| $27.6M | 20.43% |
+320,000
| New | +$19.2M |
|
|
3
Relay Therapeutics
RLAY
$4.24B
| $16.6M | 12.31% |
+400,000
| New | +$18.1M |
|
|
4
Nurix Therapeutics
NRIX
$2.45B
| $14.8M | 10.99% |
+451,522
| New | +$15M |
|
5
Hims & Hers Health
HIMS
$6.26B
| $12.7M | 9.42% |
+871,422
| New | +$9.68M |
|
|
PHICU
6
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
| $10M | 7.43% |
+960,000
| New | +$9.89M |
|
|
PNT
7
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $4.87M | 3.61% |
+350,000
| New | +$4.86M |
|
8
Tango Therapeutics
TNGX
$4.49B
| $4.58M | 3.39% |
+400,000
| New | +$4.21M |
|
|
SNCE
9
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $4.27M | 3.16% |
+20,000
| New | +$4.16M |
|
10
MoonLake Immunotherapeutics
MLTX
$1.62B
| $2.84M | 2.11% |
+250,000
| New | +$2.65M |
|
11
AbCellera Biologics
ABCL
$1.74B
| $805K | 0.6% |
+20,000
| New | +$915K |
|
Similar funds
MAM
MLM
MCM
RP
PCM
S
VW
TP
Foresite Capital Management V's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Foresite Capital Management V, which disclosed 12 positions worth $135M. Its ten largest holdings account for 99% of the portfolio.
Its largest position is Kinnate Biopharma Inc. Common Stock: 875,001 shares worth $34.8M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets.
- Foresite Capital Management V's largest Q4 2020 buy was Kinnate Biopharma Inc. Common Stock: 875,001 shares worth $34.8M.
- Foresite Capital Management V's ten largest holdings make up 99% of its $135M portfolio in Q4 2020.
- Foresite Capital Management V disclosed 12 positions in Q4 2020, its first 13F filing on record.
Based on Foresite Capital Management V's 13F filing for Q4 2020, filed 16 Feb 2021.